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Myeloid sarcoma represents the proliferation of myeloblasts of acute myeloid leukemia (AML) at extramedullary sites. While
extramedullary involvement in AML is uncommon in itself, isolated myeloid sarcomas, that is, myeloid sarcomas without any
bone marrow involvement, are extremely rare and pose a diagnostic and therapeutic challenge. Here, we present the case of a
middle-aged woman with isolated myeloid sarcoma in the stomach—an organ seldom involved by this disease. Additionally, the
literature on the epidemiology, diagnosis, pathology, prognosis, and therapeutic options in myeloid sarcomas has been reviewed.
1. Introduction
Acute myeloid leukemia (AML) is a cancer of the myeloid
elements of the bone marrow characterized by the rapid
proliferation of abnormal blasts in the bone marrow that
interfere with normal hematopoiesis. Rarely, however, the
disease canmanifest with extramedullary organ involvement,
known as myeloid sarcoma (MS) or, previously, chloroma or
granulocytic sarcoma. Defined as the presence of prolifer-
ating myeloid blasts in an extramedullary site that disrupts
the normal architecture of the organ in which they are
found [1], MS is recognized as a distinct entity under AML
and related myeloid neoplasms in the 2008 World Health
Organization classification [2]. While commonly associated
with AML, MS has rarely been described in association
with other myeloid neoplasms, including myelodysplastic
syndrome and myeloproliferative neoplasms [1, 3, 4]. MS
can occur following, concurrently with, or preceding bone
marrow involvement of AML. Isolated MS, also known as
primary or de novo MS, represents MS without any blood
or bone marrow involvement at the time of diagnosis. This
entity can involve almost any organ system, including the
skin (“leukemia cutis”), lymph nodes, bone, brain, breast,
cervix, and visceral organs. Here, we present the case of a
middle-aged woman who was found to have isolated MS in
the stomach, a very infrequent site of involvement.
2. Case Presentation
A 52-year-old otherwise healthy female presented with a
month-long history of dyspepsia. A trial of proton-pump
inhibitor therapy proved unsuccessful and she developed
severe dysphagia and odynophagia over the ensuing three
months. Examination was unremarkable besides epigastric
tenderness. Computed tomography (CT) revealed 3-cm gas-
tric wall thickening, most prominent in the fundus and
body, extending into the gastrohepatic ligament and along
the celiac artery, inseparable from the pancreatic body and
tail. Esophagogastroduodenoscopy (EGD) showed a gastric
fundusmass and pathology revealed infiltration of the lamina
propria with large atypical cells that demonstrated nuclear
pleomorphismwith prominent nucleoli. Immunohistochem-
istry (IHC) was positive for CD4, CD33, CD34, CD43,
CD45, CD68, CD117, CD163, and lysozyme. The neoplastic
cells were, however, negative for CD3, CD5, CD8, CD20,
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Figure 1: Coronal and cross-sectional PET/CT images demonstrate
intense radiotracer uptake in the gastric region.
CD30, CD56, CD138, PAX5, cyclin D1, MUM-1, BCL-6, pan-
keratin AE1/3, TIA, myeloperoxidase, and EBER (Epstein
Barr encoded RNA) by ISH (in situ hybridization). CD10,
CD128, TdT, and BCL-2 staining were variably positive,
and the proliferation fraction (Ki-67) was 60%. However,
morphologic bone marrow examination, IHC, karyotyping,
and FISH (fluorescence in situ hybridization) using probes
designed to detect rearrangements of the c-MYC (8q24),
CDKN2A (9p21), andMLL (11q23) loci as well as t(9;22) and
t(12;21) were normal. Complete blood count (CBC) revealed
leukocytes of 3,000/𝜇L, hemoglobin of 11.8 g/dL, and platelets
of 201,000/𝜇L; the blood smear showed no circulating blasts.
A diagnosis of isolated gastric MS, monocytic subtype (by
the French American British classification), was made based
on the expression of CD34, CD117 (both blast markers),
CD4, CD68, CD163, and lysozyme (suggestive of mono-
cytic differentiation). Positron emission tomographywith CT
(PET/CT) showed intense and diffuse radiotracer uptake in
the thickened gastric wall with a maximum standardized
uptake value (SUVmax) of 14.7 that was closely associated
with adjacent liver, pancreas, and spleen (Figure 1). Induction
chemotherapy with standard-dose cytarabine and high-dose
daunorubicin [5] was begun and she improved symptomati-
cally. Follow-up EGD-guided gastric biopsy showed contin-
ued presence of MS. Similarly, follow-up PET/CT showed
persistent radiotracer uptake with SUVmax of 11.2 in the
gastric wall and perigastric region. Repeat bone marrow
biopsy showed no evidence of malignancy. Reinduction
chemotherapy with fludarabine, cytarabine, idarubicin, and
filgrastim was initiated. Subsequent PET/CT showed persis-
tent radiotracer uptake (SUVmax 12.2) and slight decrease
in size of the mass. However, EGD-guided gastric biopsy
revealed no malignant cells. Immunophenotyping was unre-
markable as well. Given the PET/CT findings, however, it
was thought that the biopsies had missed malignant sites.
Surgical resection was not recommended considering the
involvement of adjacent structures. Radiation therapy to
a total dose of 27Gy over 15 fractions was administered.
Significant reduction of metabolic activity in the gastric
region (SUVmax 6.2) was noted on a follow-up PET/CT scan.
Three months later, the patient presented with abdominal
pain and vomiting. CBC was normal, but CT scan showed
peritoneal carcinomatosis. Fine needle aspirate of a pelvic
lymph node was consistent with the previously rendered
diagnosis of MS. At this point, the patient decided to forego
active treatment and died a few weeks later.
3. Discussion
The rarity of MS is reflected by its incidence of 2–9% of all
AML cases [6–8]. IsolatedMS is even rarer; its true incidence
is probably unknown. Cases of gastric MS arising in the
context of previously diagnosed hematologic neoplasms have
been described in the literature [9–13]. However, isolated gas-
tric MS is an exceedingly rare diagnosis. In a comprehensive
review of the literature spanning almost 30 years, only 2 of
154 reported cases of isolatedMS involved the stomach [3]. To
our knowledge, there exist only two other documented cases
[14, 15].
In nearly half the cases (47%), MS is initially misdiag-
nosed, with lymphoma being the most common incorrect
diagnosis [3, 16]. Indeed, on light microscopy, the differ-
ential diagnosis of MS includes non-Hodgkin’s lymphoma,
lymphoblastic leukemia, melanoma, Ewing’s sarcoma, prim-
itive neuroectodermal tumor, rhabdomyosarcoma, neurob-
lastoma, medulloblastoma, undifferentiated carcinoma, blas-
tic plasmacytoid dendritic cell neoplasm, and extramedullary
hematopoiesis [8, 17, 18]. Further diagnostic studies in the
evaluation of MS should include IHC, flow cytometry, cyto-
genetic studies, and molecular and genetic mutation analysis
on both the malignant mass and bone marrow to evaluate for
low level marrow involvement in the absence of gross disease.
CT or PET/CT can be used to image the tumor and monitor
response to treatment [8].
Previous studies had indicated that the core-binding
factor (CBF) abnormality t(8:21) was the most common
cytogenetic abnormality associated with MS formation [19,
20]. However, in an Italian study of 92 MS cases, t(8:21) was
rare (2.2%), while monosomy 7 (10.8%), trisomy 8 (10.4%),
and mixed lineage leukemia (MLL) rearrangements (8.5%)
were the commonest abnormalities [1]. Another study from
Canada that analyzed 331 cases of de novo AML (101 with
extramedullary involvement and 230 without) showed that
t(8:21) was present in only 3.9% of extramedullary cases and
5.7% of cases without extramedullary involvement, a differ-
ence that was statistically insignificant [21]. The association
of MS with t(8:21) may have been biased by analyses of
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large pediatric cohorts; in such cases, orbital involvement
was the most common presentation [1, 20]. In adults, t(8:21)
was more commonly associated with paraspinal involvement
[20]. In the Canadian study, the only cytogenetic abnormality
with a statistically significant different incidence between
the groups was the 11q23 abnormality (11.7% versus 2.1%).
Other notable differences between the groups included a
higher incidence of AML M4 (36.6% versus 25.6%), AML
M5 (18.8% versus 9.6%), CD56 expression (22.3% versus
9.9%), and leukocytosis (28,100/𝜇L versus 9,500/𝜇L) in cases
with extramedullary involvement. The Italian study had
shown CD68/KP1 to be the most commonly expressed
marker (100%), followed by myeloperoxidase (83.6%), CD117
(80.4%), CD99 (54.3%), CD68/PG-M1 (51%), CD34 (43.4%),
terminal-deoxynucleotidyl-transferase (31.5%), CD56 (13%),
CD61/linker for activation of T cells (2.2%), CD30 (2.2%),
and CD4 (1.1%). Taken together, key observations from
the two studies mentioned above include the association
of 11q23 abnormalities, CD56 expression, and AML with
myelomonocytic/monoblastic differentiation (M4/M5a)with
MS formation. A retrospective study showed that 17 out of
20 cases of MS associated with inv(16), the other CBF abnor-
mality in AML, had abdominal involvement with intestine
being the most common site (13 of 17 cases) [22]. Unfortu-
nately, inadequate tissue for analysis precluded cytogenetic or
molecular profiling of our patient’s MS.
MS has traditionally been considered a poor risk factor in
AML. Whether it truly confers a poor prognosis is, however,
uncertain. A retrospective study showed a nonsignificantly
increased two-year event free (32% versus 18%) and overall
survival (OS; 43% versus 29%) in isolated MS as compared
to leukemic AML [23]. The optimal treatment of isolated
MS is unclear, given the rarity of the diagnosis, variabil-
ity in presentation, and the lack of prospective studies.
A retrospective study evaluated the time to a diagnosis
of leukemic AML in patients diagnosed with isolated MS
treated with surgical, radiation, or systemic chemotherapy
and showed that this time period was significantly longer
in patients treated with systemic chemotherapy (median 3
months, 6 months, and 12 months, resp.) [16]. Similarly,
another retrospective study showed that early initiation of
antileukemic chemotherapy was associated with significantly
lower probability of developing leukemic AML (41% versus
71%) andwith longer survival (>50% alive at amedian follow-
up of 25months comparedwithmedian survival of 13months
for those initially untreated) [24]. Treatment of isolated MS
similar to leukemic AML with induction chemotherapy is
now standard. It is notable that isolated MS almost always
proceeds to frank leukemia, although cases without pro-
gression even upon long-term follow-up have been reported
[6, 25]. It is possible that subclinical involvement of the
bone marrow, as documented in rare cases using RT-PCR for
gene fusion transcripts, contributes to disease progression in
patients treated with local therapies only [26, 27]. However,
this has not been clearly established. Currently, surgical
and radiation therapy are accepted treatment modalities;
however, their precise roles in the treatment algorithm are not
well defined [8]. Rapid symptomatic relief, initial debulking,
inadequate response to chemotherapy, and recurrence after
hematopoietic stem cell transplantation (HSCT) are some of
the indications for these ancillary therapeutic modalities [8].
Nevertheless, the effectiveness of these therapies in addition
to induction chemotherapy as compared to chemotherapy
alone is unknown [8, 24, 28]. The role of allogeneic HSCT
was evaluated in a retrospective cohort study involving
99 patients [29]. The study showed no differences in 5-
year leukemia-free and OS rates between the isolated and
leukemic MS groups. The 5-year leukemia-free and OS
were 36% and 48%, respectively, for the entire cohort, thus
favoring allogeneic HSCT. Results from the aforementioned
Italian study corroborate this finding [1]. Patients treatedwith
HSCT were more frequently long-term survivors, whereas
those who received conventional therapiesmost often rapidly
died of their disease (OS at 48 months: 76 versus 0%) [1].
Even those who died after transplant had better survival
(mean: 41 months) than those who underwent conventional
chemotherapy, imatinib, surgery, or radiotherapy (mean: 7.1
months, 5.6 months, 36 days, and one week, resp.) [1].
Although a retrospective study from a Taiwanese institution
did not show any difference in prognosis between patients
who underwent allogeneic HSCT and those who did not, the
result could have been affected by the small number (4) of
patients who underwent HSCT [6]. Several excellent reviews
have addressed the management of MS [8, 30, 31].
4. Conclusion
Isolated MS is an extremely rare disease and isolated gastric
MS even more so. Like all isolated MS cases, it poses
diagnostic challenges, given its rarity. Clinical suspicion is the
key to correct diagnosis. Morphologic evaluation, along with
IHC, flow cytometry, cytogenetics, and molecular studies
should be performed and systemic treatment for AML, with
or without local therapies, pursued.
Conflict of Interests
The authors have no conflict of interests relevant to this paper
to disclose.
References
[1] S. A. Pileri, S. Ascani, M. C. Cox et al., “Myeloid sarcoma:
clinico-pathologic, phenotypic and cytogenetic analysis of 92
adult patients,” Leukemia, vol. 21, no. 2, pp. 340–350, 2007.
[2] J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision
of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: rationale and impor-
tant changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009.
[3] J. C. Byrd, W. J. Edenfield, D. J. Shields, and N. A. Dawson,
“Extramedullary myeloid cell tumors in acute nonlymphocytic
leukemia: a clinical review,” Journal of Clinical Oncology, vol. 13,
no. 7, pp. 1800–1816, 1995.
[4] R. S. Neiman,M. Barcos, andC. Berard, “Granulocytic sarcoma:
a clinicopathologic study of 61 biopsied cases,” Cancer, vol. 48,
no. 6, pp. 1426–1437, 1981.
[5] H. F. Fernandez, Z. Sun, X. Yao et al., “Anthracycline dose
intensification in acute myeloid leukemia,” The New England
Journal of Medicine, vol. 361, no. 13, pp. 1249–1259, 2009.
4 Case Reports in Hematology
[6] T. Lan, D. Lin, H. Tien, R. Yang, C. Chen, and K. Wu,
“Prognostic factors of treatment outcomes in patients with
granulocytic sarcoma,” Acta Haematologica, vol. 122, no. 4, pp.
238–246, 2009.
[7] S. Paydas, S. Zorludemir, andM. Ergin, “Granulocytic sarcoma:
32 cases and review of the literature,” Leukemia and Lymphoma,
vol. 47, no. 12, pp. 2527–2541, 2006.
[8] R. L. Bakst, M. S. Tallman, D. Douer, and J. Yahalom, “How I
treat extramedullary acute myeloid leukemia,” Blood, vol. 118,
no. 14, pp. 3785–3793, 2011.
[9] A. Sekaran, S. Darisetty, S. Lakhtakia, M. Ramchandani, and
D. N. Reddy, “Granulocytic sarcoma of the stomach presenting
as dysphagia during pregnancy, case reports in gastrointestinal
medicine,” Case Reports in Gastrointestinal Medicine, vol. 2011,
Article ID 627549, 3 pages, 2011.
[10] A. Wada, N. Kobayashi, S. Asanuma et al., “Repeated donor
lymphocyte infusions overcome a myeloid sarcoma of the
stomach resulting from a relapse of acute myeloid leukemia
after allogeneic cell transplantation in long-term survival of
more than 10 years,” International Journal of Hematology, vol.
93, no. 1, pp. 118–122, 2011.
[11] E. R. Choi, Y. H. Ko, S. J. Kim et al., “Gastric recurrence of
extramedullary granulocytic sarcoma after allogeneic stem cell
transplantation for acute myeloid leukemia,” Journal of Clinical
Oncology, vol. 28, no. 4, pp. e54–e55, 2010.
[12] H. Shikata, T. Matumoto, H. Teraoka, M. Kaneko, M. Nakan-
ishi, and T. Yoshino, “Myeloid sarcoma in essential throm-
bocythemia that transformed into acute myeloid leukemia,”
International Journal of Hematology, vol. 89, no. 2, pp. 214–217,
2009.
[13] K. F. Wong, R. W. S. Yuen, A. S. F. Lok, and T. K. Chan,
“Granulocytic sarcoma presenting as bleeding gastric polyp,”
Pathology, vol. 21, no. 1, pp. 63–64, 1989.
[14] E. Derenzini, S. Paolini, G. Martinelli et al., “Extramedullary
myeloid tumour of the stomach and duodenum presenting
without acute myeloblastic leukemia: a diagnostic and thera-
peutic challenge,” Leukemia and Lymphoma, vol. 49, no. 1, pp.
159–162, 2008.
[15] J. Glossmann, J. O. Staak, C. Wickenhauser, V. Diehl, and A.
Josting, “Extramedullary acute myeloid leukemia (granulocytic
sarcoma) with arm paresis, maculopapular exanthema and
organ involvement,” Leukemia and Lymphoma, vol. 44, no. 9,
pp. 1619–1621, 2003.
[16] K. Yamauchi and M. Yasuda, “Comparison in treatments of
nonleukemic granulocytic sarcoma: report of two cases and a
review of 72 cases in the literature,” Cancer, vol. 94, no. 6, pp.
1739–1746, 2002.
[17] B. A. Alexiev, W. Wang, Y. Ning et al., “Myeloid sarcomas:
a histologic, immunohistochemical, and cytogenetic study,”
Diagnostic Pathology, vol. 2, no. 1, article 42, 2007.
[18] I. W. Ngu, E. C. Sinclair, S. Greenaway, and M. L. Greenberg,
“Unusual presentation of granulocytic sarcoma in the breast: a
case report and review of the literature,” Diagnostic Cytopathol-
ogy, vol. 24, no. 1, pp. 53–57, 2001.
[19] M. S. Tallman, D. Hakimian, J. M. Shaw, G. S. Lissner, E. J.
Russell, and D. Variakojis, “Granulocytic sarcoma is associated
with the 8;21 translocation in acute myeloid leukemia,” Journal
of Clinical Oncology, vol. 11, no. 4, pp. 690–697, 1993.
[20] Y. Sugimoto, K. Nishii, M. Sakakura et al., “Acute myeloid
leukemia with t(8;21)(q22;q22) manifesting as granulocytic
sarcomas in the rhinopharynx and external acoustic meatus at
relapse after high-dose cytarabine: case report and review of the
literature,” Hematology Journal, vol. 5, no. 1, pp. 84–89, 2004.
[21] H. Chang, J. Brandwein, Q. L. Yi, K. Chun, B. Patterson, and
B. Brien, “Extramedullary infiltrates of AML are associated
with CD56 expression, 11q23 abnormalities and inferior clinical
outcome,” Leukemia Research, vol. 28, no. 10, pp. 1007–1011,
2004.
[22] X.-H. Zhang, R. Zhang, and Y. Li, “Granulocytic sarcoma
of abdomen in acute myeloid leukemia patient with inv(16)
and t(6;17) abnormal chromosome: case report and review of
literature,” Leukemia Research, vol. 34, no. 7, pp. 958–961, 2010.
[23] A. Tsimberidou, H. M. Kantarjian, S. Wen et al., “Myeloid sar-
coma is associated with superior event-free survival and overall
survival compared with acute myeloid leukemia,” Cancer, vol.
113, no. 6, pp. 1370–1378, 2008.
[24] K. R. Imrie, M. J. Kovacs, D. Selby et al., “Isolated chloroma:
the effect of early antileukemic therapy,” Annals of Internal
Medicine, vol. 123, no. 5, pp. 351–353, 1995.
[25] J. M. Meis, J. J. Butler, B. M. Osborne, and J. T. Manning,
“Granulocytic sarcoma in nonleukemic patients,” Cancer, vol.
58, no. 12, pp. 2697–2709, 1986.
[26] D.M. Lillington, R. J. Jaju, A. G. Shankar et al., “Cytogenetic and
molecular evidence of marrow involvement in extramedullary
acute myeloid leukaemia,” British Journal of Haematology, vol.
110, no. 3, pp. 547–551, 2000.
[27] T. Hayashi, M. Kimura, S. Satoh et al., “Early detection of
AML1/MTG8 fusion mRNA by RT-PCR in the bone mar-
row cells from a patient with isolated granulocytic sarcoma,”
Leukemia, vol. 12, no. 9, pp. 1501–1503, 1998.
[28] W. Y. Chen, C. W. Wang, C. H. Chang et al., “Clinicopathologic
features and responses to radiotherapy of myeloid sarcoma,”
Radiation Oncology, vol. 8, no. 1, article 245, 11 pages, 2013.
[29] P. Chevallier,M. Labopin, J. Cornelissen,G. Socie´, V. Rocha, and
M. Mohty, “Allogeneic hematopoietic stem cell transplantation
for isolated and leukemic myeloid sarcoma in adults: a report
from the acute leukemia working party of the european group
for blood and marrow transplantation,”Haematologica, vol. 96,
no. 9, pp. 1391–1394, 2011.
[30] H. Do¨hner, E. H. Estey, S. Amadori et al., “Diagnosis and man-
agement of acutemyeloid leukemia in adults: recommendations
from an international expert panel, on behalf of the European
LeukemiaNet,” Blood, vol. 115, no. 3, pp. 453–474, 2010.
[31] S. J. Slomowitz and P. J. Shami, “Management of extramedullary
leukemia as a presentation of acute myeloid leukemia,” Journal
of the National Comprehensive Cancer Network, vol. 10, no. 9, pp.
1165–1169, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
